Conflict of Interest
This website is hosted at Women’s College Hospital and was developed using funds from grants from Eczema Society of Canada and the Innovation Fund of the Alternate Funding Plan for the Academic Health Sciences Centres of Ontario. The network meta-analysis itself is not funded. There is no industry funding for this project. Updated investigator declarations from March 2022 are:
The authors declare no potential conflicts of interest involving the work under consideration for publication.
Dr Drucker has received compensation from the British Journal of Dermatology (reviewer and Section Editor), American Academy of Dermatology (guidelines writer), and National Eczema Association (grant reviewer). He has been a paid consultant for the Canadian Agency for Drugs and Technology in Health.
Dr Ellis is an employee of Stratevi, LLC, a healthcare consultancy that receives financial compensation from numerous pharmaceutical companies; Stratevi had no involvement with the submitted work.
Dr Spuls has done consultancies in the past for Sanofi (111017) and AbbVie (041217) (unpaid), was principal investigator of the MAcAD RCTs (Schram et al, JACI 2011, Roekevisch et al, JACI 2018, Gerbens et al, BJD 2018), receives departmental independent research grants for TREAT NL registry, for which she is chief investigator, from pharma companies since December 2019, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of skin conditions such as psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital.
Dr Schmitt received institutional funding for investigator-initiated trials from Novartis, Sanofi, Pfizer, ALK. He received fees for consulting from Novartis and Pfizer. He is co-principal investigatorof the German National Atopic Dermatitis Registry TREAT germany, which is funded by Sanofi Aventis Deutschland GmbH, Galderma SA, LEO Pharma GmbH, and Lilly Deutschland GmbH.
Dr Flohr is Chief Investigator of the UK National Institute for Health Research-funded TREAT (ISRCTN15837754) and SOFTER (Clinicaltrials.gov: NCT03270566) trials as well as the UK-Irish Atopic eczema Systemic Therapy Register (A-STAR; ISRCTN11210918), and a principal investigator in the European Union (EU) Horizon 2020-funded BIOMAP Consortium (http://www.biomap-imi.eu/). He also leads the EU Trans-Foods consortium. His department has received funding from Sanofi-Genzyme for skin microbiome work.
No other conflicts were reported.
Individual investigator declarations from April 2020 are as follows:
Dr. Drucker has no financial ties with any pharmaceutical company since 2017. In the last 3 years, Dr. Drucker has been a consultant for Canadian Agency for Drugs and Technology in Health. He has received honoraria from CME Outfitters, National Eczema Association, American Academy of Dermatology and British Journal of Dermatology.
Dr. Flohr is Chief Investigator of the UK NIHR-funded TREAT and SOFTER trials as well as the UK-Irish Atopic eczema Systemic Therapy Register (A-STAR) and an investigator in the Horizon 2020 funded BIOMAP Consortium. His department has also received funding from Sanofi-Genzyme for skin microbiome work.
Denise Küster and Doreen Siegels received institutional funding for IITs from Novartis, Sanofi, Pfizer, ALK.
Prof. dr. Ph.I. Spuls is chief investigator of the Governmental funded TREAT NL registry (www.treatregister.nl) and principal investigator of the MAcAD RCTs (Schram et al, JACI 2011, Roekevisch et al, JACI 2018, Gerbens et al. BJD 2018). She has done consultancies in the past for Sanofi 111017 and AbbVie 041217 (unpaid), received 2 independent research grants in the past > 5 years ago, and is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of e.g. psoriasis and atopic dermatitis for which we get financial compensation paid to the department/hospital.
Dr. Schmitt received institutional funding for IITs from Novartis, Sanofi, Pfizer, ALK. He received fees for consulting from Novartis and Pfizer. Dr. Schmitt was principle investigator of a trial included in this review. He is co-PI of the German national AD registry TREATgermany, which is funded by Sanofi.